^
    1d
    PSMACare: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=80 --> 46
    Enrollment closed • Enrollment change
    |
    FOLH1 positive
    |
    Xtandi (enzalutamide) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    1d
    A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=370, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FOLH1 positive
    |
    Xtandi (enzalutamide) • abiraterone acetate
    3d
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=37, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | N=76 --> 37
    Enrollment closed • Enrollment change
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    4d
    NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • SSTR2 (Somatostatin Receptor 2) • SYP (Synaptophysin) • CHGA (Chromogranin A)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Lutathera (lutetium Lu 177 dotatate) • AAA603
    6d
    A real-world study of 177Lu-PSMA-617 in the treatment of mCRPC (ChiCTR2500114390)
    P=N/A, N=20, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital
    New trial
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    6d
    An Exploratory Study of 177Lu-PSMA-617 in Combination with 177Lu-TBM-001 for the Treatment (Cocktail Therapy) of Metastatic Chemoresistant Prostate Cancer (mCRPC) (ChiCTR2500113787)
    P=N/A, N=30, Recruiting, West Southwest Medical University Affiliated Hospital; West Southwest Medical University Affiliated Hospital
    New trial
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    8d
    Study With [225Ac]Ac-FL-020 in mCRPC Participants (clinicaltrials.gov)
    P1, N=50, Recruiting, Full-Life Technologies GmbH | N=35 --> 50 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment change • Trial primary completion date • First-in-human
    |
    225Ac-FL-020
    8d
    Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan (clinicaltrials.gov)
    P4, N=30, Recruiting, Brigham and Women's Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    9d
    177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Jun 2027 --> Jul 2028 | Initiation date: Dec 2025 --> Mar 2026 | Trial primary completion date: Jun 2027 --> Jul 2028
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    PSAP (Prostatic Acid Phosphatase)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Provenge (sipuleucel-T)
    9d
    VALOR: Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=15, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial primary completion date
    |
    Zolinza (vorinostat) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • lutetium zadavotide guraxetan (PNT2002)
    10d
    Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone. (PubMed, J Clin Med)
    We conclude that the optimal use of PARP inhibitors, PSMA-targeted RLT, and ARPIs requires a personalized strategy guided by molecular profiling, functional imaging, prior treatment exposure, and safety considerations. This clinically focused overview aims to support evidence-based decision-making in an increasingly complex treatment landscape.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • AR (Androgen receptor) • HRD (Homologous Recombination Deficiency)
    |
    FOLH1 positive
    |
    Lynparza (olaparib) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    14d
    Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=9, Recruiting, First Affiliated Hospital of Fujian Medical University
    New P1/2 trial